Free Trial

Predictive Oncology (POAI) Insider Trading & Ownership

Predictive Oncology logo
$0.69 -0.03 (-3.82%)
(As of 12/20/2024 05:45 PM ET)

Predictive Oncology (NASDAQ:POAI) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
3.44%
Number Of
Insiders Buying
(Last 3 Years)
5
Amount Of
Insider Buying
(Last 3 Years)
$140,455.40
Number Of
Insiders Selling
(Last 3 Years)
1
Amount Of
Insider Selling
(Last 3 Years)
$30,400.00
Get POAI Insider Trade Alerts

Want to know when executives and insiders are buying or selling Predictive Oncology stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

POAI Insider Buying and Selling by Quarter

Predictive Oncology Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/25/2023Charles Lee Sr Nuzum SrDirectorSell10,000$3.04$30,400.00  
12/15/2022Daniel E HandleyDirectorBuy300$8.20$2,460.00  
12/2/2022Raymond F VennareDirectorBuy250$10.40$2,600.00  
12/2/2022Robert L MyersCFOBuy439$11.40$5,004.60  
11/29/2022Daniel E HandleyDirectorBuy500$7.20$3,600.00  
5/26/2022Daniel E HandleyDirectorBuy127$7.40$939.80  
5/24/2022J Melville EngleDirectorBuy7,975$7.40$59,015.00  
5/20/2022Charles Lee Sr Nuzum SrDirectorBuy10,000$6.20$62,000.00  
5/20/2022Robert L MyersCFOBuy806$6.00$4,836.00  
(Data available from 1/1/2013 forward)

POAI Insider Trading Activity - Frequently Asked Questions

The list of insiders at Predictive Oncology includes Charles Lee Sr Nuzum Sr, Daniel E Handley, J Melville Engle, Raymond F Vennare, and Robert L Myers. Learn more on insiders at POAI.

3.44% of Predictive Oncology stock is owned by insiders. Learn more on POAI's insider holdings.

The following insider sold POAI shares in the last 24 months: Charles Lee Sr Nuzum Sr ($30,400.00).

Insiders have sold a total of 10,000 Predictive Oncology shares in the last 24 months for a total of $30,400.00 sold.

Predictive Oncology Key Executives

  • Mr. Raymond F. Vennare (Age 71)
    CEO & Chairman
    Compensation: $525k
  • Mr. Joshua Blacher M.B.A. (Age 51)
    Interim Chief Financial Officer
  • Ms. Theresa Ferguson
    Senior Director of Marketing
  • Dr. Lawrence J. DeLucas D.Sc
    O.D, Ph.D., Senior Vice President of Biologics
  • Dr. Arlette H. Uihlein FCAP
    M.D., Senior VP of Translational Medicine & Drug Discovery and Medical Director


This page (NASDAQ:POAI) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners